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The leukocyte function-associated antigen-1 (LFA-1), the C3bi receptor (CR3) and 
the p i50,95 antigen belong to a family of leukocyte surface molecules consisting of 
bimolecular complexes with a chains of 170 kDa, 165 kDa and 150 kDa, respectively, 
and a common [3> subunit with a mol. mass of 95 kDa. In order to determine the 
function of the pl50,95 antigen on human monocytes and U937 cells, and to study the 
functional relationship between this antigen and LFA-1 or CR3, we investigated the 
influence of monoclonal antibodies (mAb) directed against these cell surface 
molecules on the adhesive properties of these cells. The observation that anti-|3 chain 
mAb strongly inhibited migration, chemotaxis, adhesion and phagocytosis of mono­
cytic cells indicates a major role for LFA-1 family antigens in monocyte functions. 
Detailed analysis with a panel of anti-a chain antibodies demonstrated that both 
pl50,95 and LFA-1 mediate random migration whereas in contrast, pl50,95 and CR3 
were shown to be involved in the directed migration of monocytes to f-Met~Leu-Phe. 
Furthermore, adhesion of monocytes to plastic surfaces or monolayers of endothelial 
cells as well as phagocytosis of latex particles was mediated by pl50,95.
The results demonstrate that, in spite of its relative low expression, the pl50,95 
glycoprotein is a major adhesion-associated molecule expressed by human monocytic 
cells.
1 Introduction
The pl50,95 antigen belongs to a family of cellular adhesion 
molecules consisting of pl50,95, the leukocyte function-associ­
ated antigen-1 (LFA-1) and the C3bi receptor (CR3, Mol, 
Mac-1) [1]. All three antigens consist of an a chain with a mol. 
mass of 150, 170 and 165 kDa, respectively, and share a com­
mon p subunit with a mol. mass of 95 kDa [1-3],
CR3 is present on null cells, granulocytes and monocytes [4]. 
Monoclonal antibodies (mAB) directed against CR3 have 
been shown to inhibit granulocyte adherence [5, 6], migration 
[7] and phagocytosis of C3bi opsonized particles [8-10]. In 
addition, Dana et al. described two functional domains in 
CR3, one involved in C3bi binding and the other in stimula­
tion of granulocyte adhesion-dependent functions [11]*
LFA-1 is present on virtually all leukocytes [12,13], and acts 
as an adhesion molecule involved in cell-cell interactions 
[14, 15]. Anti-LFA-1 mAb have been demonstrated to inter­
fere with the lytic activity of cytotoxic T lymphocytes (CTL) 
[13, 15, 16] and natural killer (NK) cells [13, 17—19] and are 
able to block T helper cell-monocyte-associated functions [2] 
by preventing cell-cell contact.
In addition to the structural relationship between pl50,95, 
CR3 and LFA-1, pl50,95 has other characteristics in common 
with either CR3 or LFA-1. Similar to CR3, pl50,95 is mainly 
expressed on monocytes, granulocytes and null cells [20-22]. 
Furthermore, a rapid increase in expression of both pl50,95 
and CR3 antigens is obtained after stimulation of granulocytes 
with chemoattractant, probably by mobilization of an internal 
pool of these antigens [5, 6], In addition, mAb directed 
against pl50,95 have been shown to inhibit granulocyte adher­
ence to serum-coated glass [6, 7] but not the phagocytosis of 
C3bi opsonized particles [7], However, since Malhotra et al. 
showed that pl50,95 bound to C3bi [23], it cannot be excluded 
that, similar to CR3, p i50,95 also has two functional domains 
[23]. Recently, it has been demonstrated that pl50,95 can be 
expressed on CTL clones [24, 25] and that anti-pl50,95 mAb 
like anti-LFA-1 antibodies are able to inhibit lysis of target 
cells [25]. The inhibition occurred at the level of conjugate 
formation and in addition additive effects were observed when 
a mixture of anti-LFA-1 and anti-pl50,95 mAb were used [25]. 
Since the function of pl50,95 on human monocytes is still 
largely unknown, we investigated its role in various adhesion 
associated processes in comparison to LFA-1 and CR3. Our 
data indicate that pl50,95 is an important cellular adhesion 
molecule, contributing to all functions tested (adherence, 
chemokinesis, chemotaxis and phagocytosis).
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2 Materials and methods
2.1 Cells
The histiocytic cell line U937 was cultured in RPMI 1640 
medium supplemented with L-glutamine (2 x 10-3 m), sodium 
pyruvate (50 mg/ml), HEPES (KT2 m), penicillin (100 IU), 
streptomycin (100 ng/ml) and 10% fetal calf serum (FCS). 
U937 cells could be induced to differentiate into adherent 
macrophage-like cells by 12-O-tetradecanoylphorbol 13-ace­
tate (TPA; 10 ng/ml) [26]. TPA was dissolved in ethanol 
(10 mg/ml), diluted in medium to a concentration of 100 ^g/ml 
and stored frozen at -20 °C.
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Monocytes were isolated from buffy coats of healthy donors by 
centrifugal élutriation, as described previously [27]. Mono­
cytes obtained in this way were >95% pure, as judged by 
staining for nonspecific esterase and by staining with mono­
cyte-specific antibodies.
2.2 Antibodies
The mAb SPV-L7 (IgGi) and SPV-L11 (IgGi), both reacting 
with the a chain of LFA-1, the mAb Bear-1 (IgGi) which 
detects the a chain of CR3 (Mol, Mac-1), and the mAb Gepi-
1 (IgM) which reacts with sugar moieties on bone marrow 
cells, monocytes, granulocytes and monocytoid cell lines, were 
raised in our laboratory [2, 18]. CLB54 (IgGi) (CLB-LFA-1/ 
1) [18] and MHM-23 [19], which are directed against the (3 
chain of LFA-1 [1, 2, 19] were kindly provided by Dr. F. 
Miedema (Central Laboratory of the Netherlands Red Cross 
Blood Transfusion Service, Amsterdam, The Netherlands) 
and by Dr. A. McMichael (Nuffield Department, John Rad- 
cliffe Hospital, Oxford, GB), respectively. S-HC13 (IgG2b) 
reacts with the pl50,95 antigen [20, 21]. The chain specificity 
of SPV-L7, SPV-L11, Bear-1, CLB54 and S-HC13 was deter­
mined by immunoprecipitation studies ([2]; results not 
shown). Antibodies were purified on a Baker-Bond mAb 
HPLC column (J. T. Baker, Philipsburg, NJ).
In all experiments the mAb Rupi-1 (IgGi) which detects a 
determinant on monocytes with a molecular mass of 35 kDa 
and the mAb SAM-1 (IgG2b) which is monocyte specific and 
detects a determinant of 70 kDa, were used as controls. These 
mAb did not interfere with all functions tested.
2.3 ELISA to measure adhesion
Five X 106 monocytes or U937 cells were labeled with 100 jxl of 
Gepi-1 antibody, conjugated with horseradish peroxidase [28], 
by incubation at 4°C for 30 min. Subsequently the cells were 
washed twice with phosphate-buffered saline (PBS) containing
0.2% bovine serum albumin (BSA) and resuspended in 
RPMI 1640 (Flow Laboratories, Rockville, MD). The capac­
ity of the monocytoid cells to adhere to plastic surfaces or to 
dense monolayers of vascular endothelial cells was determined 
as described [29]. Briefly, 5 X 104 labeled monocytes or U937 
ceils were incubated in flat-bottom microtiter wells (Costar 
no. 3596, Cambridge, MA) in the presence or absence of mAb 
(dilution of ascites 1:250). After an incubation period of 
60 min at 37 °C the plates were carefully washed twice with 
100 \xl warm (37 °C) PBS/BSA. Labeling of monocytes with 
mAb Gepi-l-p.o. did not affect the adhesive properties of the 
monocytes [29].
To quantify the number of adherent cells 100 fxl TMB 
(3,3',5,5'-tetramethylbenzidine; Crystaline Sigma T2885; 
100 mg TMB/1Q ml dimethyl sulfoxide 1:100 diluted in 0.1 m 
sodium acetate, 0,006% H202, pH 6.0) were added. The reac­
tion was stopped after 5-60 min depending on the intensity of 
the colour of the reaction product, by addition of 100 [il 0.8 M 
H2S04. The staining intensity correlated directly with .the 
number of adherent cells and was determined by a calibration 
curve. Measurements were carried out with a multiscan photo­
spectrometer (Titertek, Flow Labs.) at a wavelength of 
450 nm.
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2.4 Determination of migration, chemokinesis and chemotaxis
The migration of U937 cells and monocytes was measured as 
described by Wilkinson [30], Briefly, 2x 106 cells/well were 
seeded in microtiter plates (Costar 3596) and allowed to 
migrate out of an agar droplet for 24 h, in the presence or 
absence of mAb. The areas of migration were determined 
under a microscope which was coupled to a microprocessor as 
described by Thurman [31]. Chemokinesis and chemotaxis 
were tested in a microchemotaxis chamber (Neuroprobe, 
Bethesda, MD). The chamber is divided in an upper and lower 
compartment by a 10 [nm thick polycarbonate membrane 
(Nuclepore Corp., Pleasanton, CA) with 8 \im pores. 
Two x 104 cells were added in RPMI medium containing 2% 
autologous heat-inactivated serum to the upper compartment 
in the presence or absence of mAb. Chemotaxis was measured 
by adding f-Met-Leu-Phe (fMLP, 10~7 m) dissolved in 
RPMI 1640 supplemented with 2% heat-inactivated autolo­
gous human serum to the lower compartment. Chemokinesis 
was measured by adding fMLP both to the lower and upper 
compartment. In both situations the chambers were incubated 
90 min at 37 °C and 5% C02. After this incubation the mem­
brane filter was washed and cells which migrated through the 
pores were counted microscopically. The percentage of mi­
grating cells was calculated.
2.5 Phagocytosis
Two X 105 monocytes were resuspended in 100 ¡ml RPMI 1640 
medium supplemented with 10% heat-inactivated normal 
mouse serum and cultured in teflon bags [32], followed by 
addition of 107 fluorescent monodisperse carboxylated micro­
spheres (latex beads, Polysciences Inc., Warrington, PA). The 
monocytes were incubated in the presence or absence of mAb 
for 2 h at 37 °C, 5% C02. The number of beads phagocytozed 
per monocyte were counted under the microscope. In total 200 
monocytes were counted.
2.6 Immunofluorescence
Cells were sequentially incubated (PBS containing 1% BSA 
and 0.01% sodium azide) with appropriate dilutions of the 
different mAb and fluorescein isothiocyanate (FITC)-labeled 
goat F(ab')2 anti-mouse IgG antibody (Nordic, Tilburg, The 
Netherlands) for 30 min at 0°C. The relative fluorescence 
intensity was measured by FACS IV analysis and was enumer­
ated according to the formula:
Fluorescence intensity of cells labeled with
_ , . a reactive antibody (indirect FITC-labeled)
Relative fluorescence = ----------------------------- -
Fluorescence intensity of unlabeled cells
treated with a FITC-labeled goat anti­
mouse immunoglobulin antibody
3 Results
3.1 Expression of pl50,95, LFA-1, CR3 on monocytoid cells
The expression of pl50,95, LFA-1 and CR3 on the myeloid 
ceil line U937 was low. However, when these cells were 
induced to differentiate into mature monocytes or mac­
rophage-like cells by incubation with TPA, a 3-5 times
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Table 1, Relative fluorescence intensities of monocytes and U937 cells labeled with mAb by indirect immunofluorescence as measured by 
FACS IV analysis10
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Table 2. Effects of mAb on the random migration of monocytes and 
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a) Cells were resuspended in agar and were allowed to migrate in the 
presence of mAb (10 ng/ml) for 24 h, followed by the measure­
ment of migration as described [30]. Percentages of inhibition are 
given as mean ± SD of 4 experiments. The average migration of 
control cells was 300 [¿M.
b) p < 0.001.
a) Monocytes were obtained by centrifugal élutriation [27]. 
U937 (TPA) cells were stimulated with TPA (10 ng/ml) for 
a period of 4 days, after which the fluorescence assay was 
performed. The results of a typical experiment are shown.
cytes and U937 cells, probably due to the mAb used, since 
other investigators defined a role for CR3 in this process using 
different mAb [6,  7].
3.3 Adhesion of monocytoid cells to plastic surfaces
Since adherence is required for migration [34] we investigated 
the effects of the various anti-LFA-1 family mAb on the adhe­
sion of monocytes and U937 cells. To induce the capacity to 
adhere, U937 cells were stimulated with TPA. It is shown in 
Table 3 that mAb directed against the pl5Q,95 a and against 
the common p chain had a strong inhibitory effect on the 
adhesion of U937 cells (up to 100%) and monocytes (up to 
60%) to plastic surfaces, whereas the anti-CR3 a and the anti- 
LFA-1 a mAb were not effective. These data indicate that the 
various anti-LFA-1 family mAb had differential inhibitory 
effects on the adhesive properties of monocytoid cells. Fur­
thermore, it is concluded from these data that the pl50,95 
antigen is strongly associated with adhesion despite its rela­
tively low expression on human monocytes (Table 1).
increased expression was observed (Table 1). The degree of 
expression of the antigens on TPA-stimulated U937 cells is 
comparable to that on human monocytes (Table 1). Similar 
results were obtained with the myeloid cell lines KG-1 and 
HL-60 (not shown). Furthermore, it was observed that the 
ratio in expression of pl50,95, LFA-1 and CR3 varied signifi­
cantly between the donors tested, but in all cases the expres­
sion of CR3 and LFA-1 was >pl50,95. Two mAb [Rupi-1 
(IgG,) and SAM-1 (IgG2b)] served as controls in the functional 
assays. As shown in Table 1 both mAb reacted with mono­
cytes and U937 cells.
3.2 Migration of monocytoid cells
U937 cells and monocytes have been shown to migrate spon­
taneously [33]. To determine whether pl50,95, LFA-1 and 
CR3 played a role in the migration of these cells we investi­
gated whether mAb directed against these antigens blocked 
migration.The anti-pl50,95 a, the anti-LFA-1 a and anti-p 
chain mAb inhibited migration of both cell types (Table 2). 
Particularly the anti-|3 chain mAb showed strong inhibitory 
effects. These results indicate that pl50,95, LFA-1 and prob­
ably also CR3 are associated with the motility of monocytes 
and U937 cells. Furthermore, the results demonstrate that the 
anti-CR3 a chain mAb did not affect the migration of mono-
3.4 Adhesion of monocytoid cells to endothelial cells
LFA-1 has been described to act as a cellular adhesion 
molecule with an important role in lymphoid cell-cell interac­
tions [13-15]. The anti-LFA-1 mAb used here did not block 
the adhesion of monocytoid cells to artificial substrates such as 
plastic surfaces (Table 3). Since monocytes extravasate to 
migrate into tissues it may be possible that LFA-1 is involved 
in adhesion of these cells to vascular endothelial cells. There­
fore, we tested the effects of the various anti-LFA-1 family 
mAb on the adhesion of monocytes and TPA-stimulated U937 
cells to a confluent monolayer of vascular endothelial cells 
obtained from umbilical veins. In the absence of mAb, mono­
cytes but not U937 cells adhered to the monolayers of vascular 
endothelial cells. Adhesion of monocytes could be blocked by 
mAb recognizing the pl50,95 a chain or the common p chain 
but not by anti-LFA-1 a chain or anti-CR3 a chain mAb 
(Table 4),
In addition we excluded that the Fc receptor was involved in 
the adhesion of the monocytes to plastic or the endothelial 
cells, since ELISA and immunofluorescence experiments 
demonstrated that the mAb did not bind to endothelial cells or 
adhered nonspecifically to plastic [35]. These results provide 
evidence that the pl50,95 antigen plays a physiological role in 
the adhesion of monocytes to natural substrates.
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Table 3. Effects of mAb on the adherence of monocytes and U937 Table 5. Effects of mAb on the chemokinesis and chemotaxis of 
cells to plastic surfacesa) human monocytesa)
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TPA-treated U937 cells and monocytes were allowed to adhere in 
the presence of mAb (10 ng/ml) for 1 h, followed by the measure­
ment of the number of adherent cells (see Sect. 2.3). In the ab­
sence of mAb ^95% of the cells became adherent. Percentage 
inhibition is given as mean ± SD of 4 experiments, 
p < 0.001.
Table 4. Effects of mAb on the adherence of monocytes to vascular 
endothelial cellsa)
a) Chemotaxis and chemokinesis of human monocytes was measured 
in micro chemotaxis chambers (in triplicate) in the presence of 
10-8 M fMLP and mAb (10 |xg/ml). In the absence of inAb the 
mean percentage of cells exhibiting chemokinesis was 10, whereas 
the mean percentage of cells exhibiting chemotaxis was 28, Percen­
tage inhibition is given as mean ± SD of 4 experiments.
b) p < 0.005.
c) p < 0.025,
d) p <  0.01.
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a) TPA-treated U937 cells and monocytes were added to confluent 
monolayers of vascular endothelial cells, followed by an incuba­
tion for 2 h at 37 °C in the presence of mAb (10 pg/ml). The 
number of adherent cells was determined as described in Sect, 2, 
In the absence of mAb, TPA-treated U937 cells did not become 
adherent to endothelial cells. Therefore, the percentage inhibition 
could not be determined. The number of monocytes which became 
adherent always exceeded 30%. Percentage inhibition is given as 
mean ± SD of 4 experiments.
b) p < 0.005.
Table 6. Effects of raAb on the phagocytosis of carboxylated mono- 
disperse latex beadsa)
Antigen
IgGt control (p35) 
IgG2b control 
LFA-1 a 
LFA-1 a 
CR3 a 
pl50,95 a 
Common ß 
Common ß
mAb
Rupi-1 
SAM-1 
SPV-L7 
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S-HCl 3 
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7
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5
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25
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a) Monocytes were incubated with 1.44 |xm latex beads in the pres­
ence of mAb (5 i^g/ml). After a 2-h incubation (37°C) phagocy- 
tozed beads per monocyte were counted. Similar results were 
obtained in three consecutive experiments using monocytes of 
nonrelated donors.
3.5 Chemotaxis and chemokinesis of monocytoid cells
To study the effects of these mAb on directed migration, the 
capacity of the mAb to inibit chemokinesis and chemotaxis of 
monocytes and U937 cells in response to fMLP was tested. 
Monocytes showed strong chemotactic and chemokinetic 
responses to fMLP whereas U937 cells treated with or without 
TPA did not respond [36]. Maximal inhibiton was observed 
after addition of anti-(3 chain antibodies, whereas of the anti-a 
chain antibodies pl50,95 mAb were most effective (Table 5). 
Furthermore, anti-CR3 mAb showed similar inhibitory effects 
in contrast to anti-LFA-1 mAb which did not block directed or 
random migration, These results indicate that pl50,95 and 
CR3 are involved in chemokinesis and chemotaxis of human 
monocytes.
3.6 Phagocytosis of latex beads by monocytoid cells
Another important function of monocytes is their capability to 
phagocytose. To investigate the antigens involved in this pro­
cess, phagocytosis blocking studies were performed with the 
LFA-1 family mAb. Table 6 shows the number of carboxy­
lated latex beads ingested by each monocyte in the presence of 
different mAb. Anti-pl50,95 a chain and anti-|3 chain mAb 
blocked the uptake of latex beads equally well. Both anti- 
LFA-1 a chain and anti-CR3 a chain antibodies were ineffec­
tive. These results, together with the results from Sects. 3.3 
and 3.4, indicate that p i50,95 is an important general adhesion 
molecule, since it exhibits low substrate specificity.
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4 Discussion
mAb directed against the common (3 chain of the LFA-1 family 
inhibit adhesion, chemotaxis and phagocytosis of human 
monocytes [3,18, 19, 37], These data do not allow identifica­
tion of the function of each member of this family, since bind­
ing of an anti-p chain mAb can affect the function of LFA-1, 
CR3 and pl50,95. Although the function of CR3 and pl50,95 
has been investigated on human granulocytes [6, 7, 9,11], less 
is known on the role of these molecules on human monocytes. 
In the present report we show that pl50,95 plays an important 
role in adhesion-associated functions of human monocytes. 
mAb directed against the a  chain of pl50,95 and the common 
p chain were potent inhibitors of adhesion, migration, 
chemotaxis and phagocytosis of human monocytes and inhib­
ited the adhesion of TP A stimulated U937 cells. In contrast, 
antibodies directed against the a chains of LFA-1 and CR3 
were less efficient in their blocking properties and only 
affected random migration (LFA-1) and chemotaxis (CR3). 
Previous studies, however, clearly demonstrated that both the 
anti-a chain LFA-1 and the anti-a chain CR3 antibodies used 
in this study, recognize functional epitopes since they inhibit 
conjugate formation between effector and target cells [25, 35].
The differences observed in the capacity of the anti-pl50,95 
and anti-common (3 chain antibodies to block adhesion of 
TPA-treated U937 cells or monocytes were not related to the 
level of expression of LFA-1, CR3 or pl50,95, since both cell 
types expressed equal amounts of these antigens (Table 1). 
This finding may indicate the involvement of additional 
molecules in adhesion-related processes of human monocytes 
or granulocytes and is in line with data of Wallis et al. and 
Harlan et aL who observed that mAb directed against the 
common (3 chain never completely abrogated the adhesion of 
monocytes or neutrophils to endothelial cells [38, 39]. Similar 
findings were made by Anderson et al. [7] who applied mix­
tures of mAb directed against all peptides of the LFA-1 family 
to study granulocyte adhesion.
The role of each of the LFA-1 family antigens in random 
migration is difficult to define since cell migration is a complex 
process in which both adhesion and motility play an important 
role [34, 40]. It is even more difficult to determine the function 
of these molecules in migration upon stimulation with 
chemotactic compounds such as fMLP, because rapid 
increases in the expression of CR3 and pl50,95 on monocytes 
(unpublished data) and granulocytes [6, 41, 42] are observed. 
Our data demonstrate that pl50,95 plays a major role in cell 
motility, cell adhesion and chemotaxis. In addition, from our 
data and from results presented by others, it seems fair to 
conclude that both LFA-1 and CR3 also can participate in 
these processes. This notion is derived from the results of 
inhibition studies. These studies show that anti-p chain mAb 
are more potent inhibitors of adhesion and chemotaxis than 
anti-a chain antibodies alone [37, 39, 41-43], whereas an 
increased inhibition was observed when a selected mixture of 
mAb directed against all three a chains and against the com­
mon (3 chain of the LFA-1 family were applied [39], Similarly, 
we demonstrated that pl50,95 is involved in phagocytosis 
whereas other investigators showed that LFA-1 [44] or CR3 
[6, 9, 44] mediate phagocytosis applying different targets.
As discussed above, anti-(3 chain mAb interfere with all func­
tions associated with LFA-1, CR3 or pl50,95. Therefore, it 
cannot be excluded that the (3 chain by itself contributes to the
adhesion reaction. Despite a possible role in adhesion, the 
function of the common (3 chain is not clearly understood. It 
has been suggested that it acts as a transport molecule for the 
various a chains [1, 41], comparable to |32-microglobulin which 
has been shown to act as a vehicle to insert major histocom­
patibility complex antigens into the cell membrane [45], This 
notion is supported by studies in patients deficient for LFA-1, 
p i50,95 and CR3 [46-48]. These patients have a very low level 
of (3 chain precursor in contrast to LFA-1 a chain and CR3 a 
chain precursors [41, 44]. Until now it was not possible to 
relate the functional deficiencies of monocytes and granulo­
cytes observed in these patients to one or more of the LFA-1 
family antigens.
The observations presented in this study indicate that the 
LFA-1, CR3 and pi50,95 antigens ail contribute to many 
adhesion-related reactions each with its own specificity. A 
detailed analysis of the binding sites of these molecules by 
antibodies reacting with different epitopes of the same antigen 
and elucidation of their respective counterstructures will be 
helpful to further define the function of these adhesion-associ­
ated glycoproteins.
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